United States Brent Oil Fund LP vs Johnson & Johnson — how do they compare? United States Brent Oil Fund LP trades at $47.14, while Johnson & Johnson trades at $247.5 (market cap $611.07B). The key difference: Johnson & Johnson pays a 2.11% dividend while United States Brent Oil Fund LP pays none, and Johnson & Johnson is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.
| BNO | JNJ | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $267.24 |
52-Week Low | $27.20 | $155.17 |
Market Cap | — | $611.07B |
Volume | — | 6,156,228 |
Enterprise Value | — | $644.01B |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
BNO, a US-listed oil-focused stock, trades at $46.00, up 9.13% on the day, driven by escalating Middle East tensions that have pushed crude prices to one-month highs. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 86 suggests overbought conditions. Recent news highlights supply risks from U.S.-Iran hostilities, including blockades and strikes, which are boosting energy sector sentiment and driving volatility.
The outlook for BNO remains heavily tied to geopolitical developments and oil price momentum. Upside potential exists if supply disruptions persist, but risks include rapid de-escalation or demand weakness. Investors should weigh the stock's sensitivity to crude fluctuations against current bullish technical and sentiment signals.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →